2006 Gi-5005 Therapeutic Vaccine Plus Peg-ifn/ribavirin Significantly Improves Virologic Response and Alt Normalization at End-of-treatment and Improves Svr24 Compared to Peg-ifn/ribavirin in Genotype-1 Chronic Hcv Patients
Year: 2010
Type: article
Study design: Clinical Trial
Source: Journal of Hepatology
Institutions: Weill Cornell Medicine, Orlando Clinical Research Center, Duke Medical Center, Scripps Clinic, Duke Clinical Research Institute, University of Arizona, Quest Clinical Research (United States), Altasciences Clinical Research Vince & Associates, University of Miami, Ponce Health Sciences University, University of Colorado Denver, Orlando Immunology Center, University of Oklahoma - Tulsa, University of Oklahoma, Saint Thomas West Hospital, Baylor St. Luke's Medical Center, Baylor College of Medicine, Nashville Medical Research Institute, Gilead Sciences (United States), Infectious Diseases and the Research Institute, Pfizer (United States), Swedish Medical Center, University of Hawaiʻi at Mānoa, University of Hawaii System, Bon Secours Health System, GlobeImmune (United States)
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1984566141